| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07285785 | Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute… | Diarrhea | Recruiting |
| NCT07426705 | Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy… | Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Not Yet Recruiting |
| Phase 3 | |||
| NCT07522255 | Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders | Bloating | Not Yet Recruiting |
| Phase 2 | |||
| NCT06727422 | Efficacy of Rifaximin With NAC in IBS-D | IBS (Irritable Bowel Syndrome) | Recruiting |
| NCT07209371 | Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of… | IgA Monoclonal Gammopathy of Undetermined Significance | Recruiting |
| Phase 1 | |||
| NCT05159427 | Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers | Human Gastrointestinal Physiology Data | Recruiting |
| Early Phase 1 | |||
| NCT07381257 | Efficacy and Safety of Rifaximin-α in Treating MASLD | Metabolic Dysfunction-Associated Steatotic Liver Disease | Recruiting |